University of Maryland, Baltimore
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).
University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.
University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.
Top-decile sponsor footprint
University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
560 total, page 12 of 12
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00003401
BHS4 - Bone/Muscle Changes Following Hip Fracture in Older White Women
NCT00390741
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
NCT00003398
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Prostate Cancer
NCT00003400
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma
NCT00003399
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
NCT00003397
Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
NCT00003396
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT00003413
Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors
NCT00002677
Trial of Home Visitation Among Infants With Failure To Thrive
NCT00483691
What is open in the University of Maryland, Baltimore pipeline
103 recruiting of 560 indexed (18% open); 332 completed (59%).
Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (14 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Maryland, Baltimore: open-pipeline peers nationwide
Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 560 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this University of Maryland, Baltimore page
560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.
- 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.